Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. reports developments in sleep health, respiratory care and home healthcare technology. The company supplies sleep apnea and breathing-care devices, including CPAP platforms such as AirSense 11, and supports them with cloud-connected software, AI-enabled digital health tools and patient data applications used in out-of-hospital care.
Recurring updates include quarterly operating results, demand trends for sleep and respiratory care products, FDA-cleared digital medical devices such as Smart Comfort, supply-chain and distribution capacity, shareholder returns, executive leadership changes and investor conference presentations. ResMed’s announcements also reflect its NYSE-listed common stock and ASX-traded presence.
Resmed (NYSE: RMD) announced that director Carol Burt has been appointed to become Lead Director effective November 15, 2026, succeeding Ron Taylor. Taylor, who has served on Resmed’s board since 2005 and as Lead Director since 2013, will not stand for reelection at the 2026 Annual Meeting of Stockholders on November 18, 2026 and will retire after more than 21 years of service. Burt has been a director since 2013, chairs the Nominating and Governance Committee, and serves on the Audit and Compliance, Privacy and Quality Committees, which Resmed highlights as strong preparation for her Lead Director role.
Resmed (NYSE: RMD) reported Q4 FY2026 revenue of $1.46 billion, up 9% (8% in constant currency), with GAAP diluted EPS of $2.64 and non-GAAP diluted EPS of $2.95, up 16%. Q4 non-GAAP gross margin rose 90 bps to 62.3%, while GAAP gross margin was 58.8% including $41.9 million in Astral field safety notification expenses.
For FY2026, revenue increased 10% to $5.65 billion, GAAP gross margin improved 170 bps to 61.1%, and GAAP operating margin reached 33.4%. Non-GAAP diluted EPS grew 17% to $11.17. Free cash flow was $1.65 billion, supporting $1.0 billion of capital returned to shareholders, over 70% higher than the prior year. Resmed guided to returning more than $1.85 billion in FY2027 and raised its quarterly dividend by 10% to $0.66 per share. The company agreed to sell its MatrixCare business, completed the Noctrix Health acquisition, and launched new AirSense 11 and AirCurve 11 devices in multiple markets.
Frazier Healthcare Partners announced a definitive agreement to acquire MatrixCare from Resmed (NYSE: RMD). MatrixCare provides cloud-based EHR software for out-of-hospital care, including skilled nursing, senior living, home health, hospice, and life plan communities.
The deal covers MatrixCare and related software brands and is expected to close in Q3 2026, subject to customary conditions. Resmed describes the divestiture as aligned with its 2030 portfolio strategy.
Resmed (NYSE:RMD) entered a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a healthcare-focused private equity firm. The deal aligns with Resmed’s 2030 strategy to prioritize high-growth sleep, breathing and connected home-based care and to reallocate capital toward innovation and operational scale.
The sale covers MatrixCare and related brands, including Healthcare First and Citus, but excludes Brightree and MEDIFOX DAN. Closing is targeted for the first quarter of Resmed’s fiscal 2027, subject to regulatory approvals and customary conditions. MatrixCare will operate within Resmed until completion.
Resmed (NYSE:RMD) will release its fourth quarter fiscal 2026 financial and operational results on Thursday, August 6, 2026, after the NYSE closes.
Management will host an earnings webcast at 1:30 p.m. PT / 4:30 p.m. ET, accessible only via the investor relations website, with replay options available.
Resmed (NYSE:RMD) has completed its acquisition of Noctrix Health, a wearable-therapeutics company for chronic neurological disorders. The deal adds Noctrix’s Nidra TOMAC Therapy, an FDA De Novo classified, non-invasive, non-pharmacologic treatment for moderate-to-severe Restless Legs Syndrome (RLS), to Resmed’s clinical sleep health portfolio.
Noctrix becomes a wholly owned Resmed subsidiary, supporting Resmed’s 2030 strategy by expanding into RLS, the third most prevalent sleep disorder, with a clinically validated therapy backed by 10 peer-reviewed publications and inclusion in AASM clinical practice guidelines.
Resmed (NYSE:RMD) announced that chairman and CEO Mick Farrell and CFO Aaron Bloomer will participate in the 46th Annual William Blair Growth Stock Conference in Chicago on June 2, 2026. A live, audio-only webcast starts at 4:40 p.m. CT, with a replay available for 90 days.
Resmed (NYSE:RMD) and Oura announced a partnership to expand access to sleep health education and care pathways for Oura Ring members in the U.S.
Oura Ring Gen3 and Ring 4 users with active memberships can access Resmed educational tools, sleep assessments, and options to connect with independent healthcare providers.
Resmed (NYSE: RMD) announced that CFO Brett Sandercock will retire effective May 4, 2026, and Aaron Bloomer will succeed him as CFO. Sandercock will advise the CEO through end of 2027. The company reiterated fiscal 2026 outlook: gross margin 62–63%, SG&A 19–20%, R&D 6–7%, effective tax rate 21–23%.
Resmed (NYSE: RMD) reported Q3 FY2026 results for the quarter ended March 31, 2026: revenue $1.431B (up 11% reported, 8% constant currency), GAAP gross margin 62.2% (+290 bps), GAAP diluted EPS $2.74 and non-GAAP diluted EPS $2.86 (+21%).
Operating cash flow was $554M; the company returned $262M to shareholders via $175M buybacks and $87M dividends, and declared a quarterly dividend of $0.60 per share.